Form 4: Medpace Executive VP Files Form 4 for Future Stock Sale

Medpace Holdings, Inc. Executive Vice President of Operations, Susan E. Burwig, reported a pre-planned sale of 7,500 shares of common stock scheduled for July 28, 2025, at a weighted average price of $450.14 per share.

Summary

• Susan E. Burwig, Executive Vice President of Operations at Medpace Holdings, Inc. (MEDP), reported a planned disposition of common stock.
• The transaction involves the sale of 7,500 shares of common stock.
• The sale is scheduled to occur on July 28, 2025.
• The shares were sold at a weighted average price of $450.14, with individual transactions ranging from $450.00 to $450.43.
• Following this transaction, Ms. Burwig will beneficially own 57,500 shares of Medpace Holdings, Inc. common stock directly.
• The sale was executed pursuant to a limit order placed by the Reporting Person during an open window period, indicating a pre-planned transaction.

Sentiment

Score: 5

Explanation: A neutral sentiment. While an insider sale can be perceived negatively, the filing explicitly states it was a pre-planned transaction (limit order during an open window period) for a future date, which mitigates the negative signal often associated with unannounced insider selling. It appears to be a routine financial planning event for the executive.

Negatives

• An executive selling shares, even if pre-planned, can sometimes be perceived negatively by the market, potentially suggesting a lack of confidence or a desire to diversify holdings.
• The transaction reduces the executive's direct ownership stake in the company by 7,500 shares.

Future Outlook

NA

Management Comments

• The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.

Industry Context

This filing is a standard insider transaction report and does not provide broader industry context. It reflects an individual executive's financial planning rather than a company-wide strategic move or industry trend.

Stakeholder Impact

• Shareholders: The planned sale of shares by a key executive could lead to minor concerns about insider confidence, though the pre-planned nature and future date of the transaction mitigate this impact.

Key Dates

Recommendation

The filing details a routine, pre-planned sale of a relatively small number of shares by an executive, scheduled for a future date. This type of transaction, especially when pre-arranged under a Rule 10b5-1-like plan, typically does not signal a fundamental change in the company's prospects or warrant a change in investment strategy. Investors should hold their positions and monitor broader company performance and market trends.

Keywords

Medpace Holdings, MEDP, Insider Trading, Form 4, Stock Sale, Executive Compensation, Susan E. Burwig, Common Stock